141P Phase Ib Study of the TLR7 Agonist TQ-A3334 Monotherapy or Combined with Anlotinib or PD-L1 Inhibitor in Treatment of Advanced Metastatic Non-Small Cell Lung Cancer
Y. Song,T. Lv,G. N. Wu,J. Z. Rui,X. Zuo
DOI: https://doi.org/10.1016/j.annonc.2021.10.160
IF: 51.769
2021-01-01
Annals of Oncology
Abstract:BackgroundTQ-A3334 is a newly developing Toll-like receptor (TLR)-7 agonist. TLR7 activation induces secretion of proinflammatory cytokines including IFN-α, IL-12 and TNF-α, and enhances DC maturation and antigen presentation.MethodsThe study was a multi-center, Phase 1b study of TQ-A3334 as monotherapy and combination with Anlotinib or TQ-B2450 in advanced metastatic NSCLC with ≥2 prior chemotherapy lines, including TQ-A3334 (q1w) dose escalation, followed by expansion into indication specific arms to test for efficacy in defined patient cohorts. Patients could re-receive the treatment of TQ-A3334 in combination with Anlotinib (10 mg qd, d1-d14, 21 days per cycle) or TQ-B2450 intravenously (1200 mg, q3w), assessed by investigators after disease progress occurred in monotherapy dose escalation phase. The primary endpoints of dose escalation are to identify the MTD/RP2D and characterize safety/tolerability. Secondary objectives include an assessment of efficacy (best overall response by RECIST v1.1), PK and PD.TQ-A3334 monotherapy dose escalation is in progress.ResultsAs of 15 July 2021, 9 patients (8 PD-(L)1 inhibitor resistance patients) were enrolled for 4 dose-levels (1mg: n=1; 1.5mg: n=4; 2.0mg: n=3; 2.5mg: n=1) in dose escalation phase.The most frequently reported drug-related adverse events were of CTC Grade ≤2. No DLTs were observed and MTD was not reached. The most common drug-related adverse events were mild-to-moderate “flu-like” symptoms, including fever (n=8, 88.9%), cough (n=3, 33.3%), etc.There was no relationship between toxicity and dose and no patient withdrew from the study due to drug-related AE.Among the 7 patients evaluable for efficacy, 3 patients achieved stable disease during TQ-A3334 monotherapy. While there were 2 patients whose PFS were above the 4 months, and they achieved partial response during treatment of TQ-A3334 combined with Anlotinib after TQ-A3334 monotherapy.ConclusionsTQ-A3334 is tolerated during 1.0mg-2.0mg level in the advanced metastatic NSCLC. TQ-A3334 in combination with Anlotinib demonstrated encouraging anti-tumor activity in advanced metastatic NSCLC.Clinical trial identificationNCT04273815.Legal entity responsible for the studyChia Tai Tianqing Pharmaceutic Group Co. Ltd.FundingChia Tai Tianqing Pharmaceutic Group Co. Ltd.DisclosureAll authors have declared no conflicts of interest. BackgroundTQ-A3334 is a newly developing Toll-like receptor (TLR)-7 agonist. TLR7 activation induces secretion of proinflammatory cytokines including IFN-α, IL-12 and TNF-α, and enhances DC maturation and antigen presentation. TQ-A3334 is a newly developing Toll-like receptor (TLR)-7 agonist. TLR7 activation induces secretion of proinflammatory cytokines including IFN-α, IL-12 and TNF-α, and enhances DC maturation and antigen presentation. MethodsThe study was a multi-center, Phase 1b study of TQ-A3334 as monotherapy and combination with Anlotinib or TQ-B2450 in advanced metastatic NSCLC with ≥2 prior chemotherapy lines, including TQ-A3334 (q1w) dose escalation, followed by expansion into indication specific arms to test for efficacy in defined patient cohorts. Patients could re-receive the treatment of TQ-A3334 in combination with Anlotinib (10 mg qd, d1-d14, 21 days per cycle) or TQ-B2450 intravenously (1200 mg, q3w), assessed by investigators after disease progress occurred in monotherapy dose escalation phase. The primary endpoints of dose escalation are to identify the MTD/RP2D and characterize safety/tolerability. Secondary objectives include an assessment of efficacy (best overall response by RECIST v1.1), PK and PD.TQ-A3334 monotherapy dose escalation is in progress. The study was a multi-center, Phase 1b study of TQ-A3334 as monotherapy and combination with Anlotinib or TQ-B2450 in advanced metastatic NSCLC with ≥2 prior chemotherapy lines, including TQ-A3334 (q1w) dose escalation, followed by expansion into indication specific arms to test for efficacy in defined patient cohorts. Patients could re-receive the treatment of TQ-A3334 in combination with Anlotinib (10 mg qd, d1-d14, 21 days per cycle) or TQ-B2450 intravenously (1200 mg, q3w), assessed by investigators after disease progress occurred in monotherapy dose escalation phase. The primary endpoints of dose escalation are to identify the MTD/RP2D and characterize safety/tolerability. Secondary objectives include an assessment of efficacy (best overall response by RECIST v1.1), PK and PD.TQ-A3334 monotherapy dose escalation is in progress. ResultsAs of 15 July 2021, 9 patients (8 PD-(L)1 inhibitor resistance patients) were enrolled for 4 dose-levels (1mg: n=1; 1.5mg: n=4; 2.0mg: n=3; 2.5mg: n=1) in dose escalation phase.The most frequently reported drug-related adverse events were of CTC Grade ≤2. No DLTs were observed and MTD was not reached. The most common drug-related adverse events were mild-to-moderate “flu-like” symptoms, including fever (n=8, 88.9%), cough (n=3, 33.3%), etc.There was no relationship between toxicity and dose and no patient withdrew from the study due to drug-related AE.Among the 7 patients evaluable for efficacy, 3 patients achieved stable disease during TQ-A3334 monotherapy. While there were 2 patients whose PFS were above the 4 months, and they achieved partial response during treatment of TQ-A3334 combined with Anlotinib after TQ-A3334 monotherapy. As of 15 July 2021, 9 patients (8 PD-(L)1 inhibitor resistance patients) were enrolled for 4 dose-levels (1mg: n=1; 1.5mg: n=4; 2.0mg: n=3; 2.5mg: n=1) in dose escalation phase.The most frequently reported drug-related adverse events were of CTC Grade ≤2. No DLTs were observed and MTD was not reached. The most common drug-related adverse events were mild-to-moderate “flu-like” symptoms, including fever (n=8, 88.9%), cough (n=3, 33.3%), etc. There was no relationship between toxicity and dose and no patient withdrew from the study due to drug-related AE. Among the 7 patients evaluable for efficacy, 3 patients achieved stable disease during TQ-A3334 monotherapy. While there were 2 patients whose PFS were above the 4 months, and they achieved partial response during treatment of TQ-A3334 combined with Anlotinib after TQ-A3334 monotherapy. ConclusionsTQ-A3334 is tolerated during 1.0mg-2.0mg level in the advanced metastatic NSCLC. TQ-A3334 in combination with Anlotinib demonstrated encouraging anti-tumor activity in advanced metastatic NSCLC. TQ-A3334 is tolerated during 1.0mg-2.0mg level in the advanced metastatic NSCLC. TQ-A3334 in combination with Anlotinib demonstrated encouraging anti-tumor activity in advanced metastatic NSCLC.